Catabasis Pharmaceuticals Company Profile (NASDAQ:CATB)

About Catabasis Pharmaceuticals

Catabasis Pharmaceuticals logoCatabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease. The Company's primary focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of lipid disorders. The Company's CAT-1004 is a SMART linker conjugate of salicylate, a non-steroidal anti-inflammatory drug, and the omega-3 fatty acid docosahexaenoic acid (DHA), a naturally occurring unsaturated fatty acid with anti-inflammatory properties. Its CAT-2000 series product candidates inhibit the Sterol Regulatory Element Binding Protein (SREBP) pathway. The Company's CAT-4001 is a SMART linker conjugate of monomethyl fumarate and DHA.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CATB
  • CUSIP:
Key Metrics:
  • Previous Close: $1.19
  • 50 Day Moving Average: $2.76
  • 200 Day Moving Average: $3.94
  • 52-Week Range: $18,652,000.00 - $1.08
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.59
  • P/E Growth: 0.00
  • Market Cap: $22.76M
  • Outstanding Shares: 18,652,000
  • Beta: 2.39
Profitability:
  • Return on Equity: -91.15%
  • Return on Assets: -69.61%
Debt:
  • Debt-to-Equity Ratio: 0.09%
  • Current Ratio: 5.65%
  • Quick Ratio: 5.65%
Additional Links:
Companies Related to Catabasis Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Catabasis Pharmaceuticals (NASDAQ:CATB) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $9.80 (703.28% upside)

Analysts' Ratings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017WedbushReiterated RatingOutperform$15.00 -> $4.00View Rating Details
2/1/2017Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
1/31/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$18.00 -> $11.00View Rating Details
2/1/2017Cowen and CompanyDowngradeOutperform -> Market Perform$4.00View Rating Details
12/22/2016HC WainwrightInitiated CoverageBuy$14.00View Rating Details
(Data available from 2/27/2015 forward)

Earnings

Earnings History for Catabasis Pharmaceuticals (NASDAQ:CATB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2017($0.52)N/AView Earnings Details
11/10/2016Q316($0.65)($0.54)ViewListenView Earnings Details
8/11/2016Q216($0.65)($0.61)ViewListenView Earnings Details
5/12/2016Q1($0.64)($0.61)ViewListenView Earnings Details
3/4/2016Q415($0.69)($0.63)ViewListenView Earnings Details
11/12/2015Q315($0.64)($0.55)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Catabasis Pharmaceuticals (NASDAQ:CATB)
Current Year EPS Consensus Estimate: $-2.28 EPS
Next Year EPS Consensus Estimate: $-2.08 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.63)($0.60)($0.62)
Q2 20162($0.65)($0.61)($0.63)
Q3 20162($0.67)($0.61)($0.64)
Q4 20162($0.61)($0.46)($0.54)
Q1 20171($0.48)($0.48)($0.48)
Q2 20171($0.50)($0.50)($0.50)
Q3 20171($0.57)($0.57)($0.57)
Q4 20171($0.65)($0.65)($0.65)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Catabasis Pharmaceuticals (NASDAQ:CATB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Catabasis Pharmaceuticals (NASDAQ:CATB)
Insider Ownership Percentage: 64.10%
Institutional Ownership Percentage: 61.43%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/30/2015Medimmune Ventures, Inc.Major ShareholderBuy223,439$12.00$2,681,268.00View SEC Filing  
6/30/2015Nicholas GalakatosDirectorBuy376,695$12.00$4,520,340.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Catabasis Pharmaceuticals (NASDAQ:CATB)
DateHeadline
openpr.com logoCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Investor Investigation over possible Violations of Securities Laws (NASDAQ:CATB)
www.openpr.com - February 22 at 4:17 PM
News IconCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Investor ... - Satellite PR News (press release) (NASDAQ:CATB)
www.satprnews.com - February 22 at 8:03 AM
businesswire.com logoCatabasis Pharmaceuticals Announces Promotion of Ted Hibben to ... - Business Wire (press release) (NASDAQ:CATB)
www.businesswire.com - February 17 at 6:01 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Announces Promotion of Ted Hibben to Chief Business Officer (NASDAQ:CATB)
finance.yahoo.com - February 17 at 6:01 PM
News IconInvestor Investigation over potential Securities Laws Violations of Catabasis Pharmaceuticals Inc (NASDAQ:CATB) (NASDAQ:CATB)
www.groundreport.com - February 13 at 4:43 PM
News IconSvlsf V, Llc. is Buying Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) Shares - Small Cap Exclusive (press release) (NASDAQ:CATB)
smallcapexclusive.com - February 9 at 4:25 PM
News IconCatabasis Pharmaceuticals Inc (NASDAQ:CATB) Shareholder Notice: Investigation over Possible Violations of Securities Laws (NASDAQ:CATB)
www.digitaljournal.com - February 8 at 4:23 PM
News IconEquity Focus: Indicator Check on Shares of Catabasis Pharmaceuticals Inc (CATB) - Rives Journal (NASDAQ:CATB)
rivesjournal.com - February 7 at 10:12 PM
News IconStock Trickling Lower Heading Into The Open: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Aiken Advocate (NASDAQ:CATB)
aikenadvocate.com - February 6 at 9:14 PM
News IconTrading Radar: Zooming in on Shares of Catabasis Pharmaceuticals Inc (CATB) - Sherwood Daily (NASDAQ:CATB)
sherwooddaily.com - February 4 at 2:24 AM
wallstrt24.com logoStocks Buzz Catabasis Pharmaceuticals Inc (NASDAQ:CATB), Hologic, Inc. (NASDAQ:HOLX) - Wall Street 24 (NASDAQ:CATB)
wallstrt24.com - February 4 at 2:23 AM
News IconCatabasis Pharmaceuticals, Inc. (NASDAQ:CATB) showed P/E ratio of 0 - The Newburgh Press (NASDAQ:CATB)
newburghpress.com - February 4 at 2:23 AM
News IconBrokers Set Expectations for Catabasis Pharmaceuticals, Inc.'s FY2021 Earnings (CATB) (NASDAQ:CATB)
eleganthomesinla.com - February 3 at 4:21 PM
us.rd.yahoo.com logo4:02 pm Catabasis Pharmaceuticals announces top-line safety and efficacy results for Part B of the MoveDMD trial of edasalonexent for the treatment of Duchenne muscular dystrophy; changes were not statistically significant (shares halted) (NASDAQ:CATB)
us.rd.yahoo.com - February 2 at 9:22 PM
businesswire.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis ... (NASDAQ:CATB)
www.businesswire.com - February 2 at 4:21 PM
News IconEarnings Forecast Research on Catabasis Pharmaceuticals, Inc. (CATB) (NASDAQ:CATB)
xboxonezone.com - February 2 at 4:21 PM
News IconCatabasis Pharmaceuticals, Inc. (CATB) Stock Rating Lowered by Cowen and Company (NASDAQ:CATB)
perspectivabetica.com - February 2 at 4:21 PM
us.rd.yahoo.com logoCatabasis Pharmaceuticals downgraded by Citigroup (NASDAQ:CATB)
us.rd.yahoo.com - February 2 at 4:21 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)
finance.yahoo.com - February 2 at 4:21 PM
smarteranalyst.com logoOppenheimer Waits for Catabasis Pharmaceuticals Inc (CATB) to Present Longer Term Data in DMD (NASDAQ:CATB)
www.smarteranalyst.com - February 2 at 2:28 AM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Apple, Catabasis, Match, Oneok Partners - Nasdaq (NASDAQ:CATB)
www.nasdaq.com - February 1 at 9:27 PM
News IconIncrease in Volatility Draws Attention to Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Wall Street Beacon (NASDAQ:CATB)
wsbeacon.com - February 1 at 9:27 PM
benzinga.com logo20 Biggest Mid-Day Losers For Wednesday - Benzinga (NASDAQ:CATB)
www.benzinga.com - February 1 at 9:27 PM
investopedia.com logoCatabasis Tanks 70% on DMD Drug Failure (CATB) - Investopedia (NASDAQ:CATB)
www.investopedia.com - February 1 at 9:27 PM
proactiveinvestors.co.uk logoCatabasis Pharmaceutical crashes as DMD trial falters (NASDAQ:CATB)
www.proactiveinvestors.co.uk - February 1 at 4:25 PM
schaeffersresearch.com logoAltria, Amazon, Catabasis News Today (NASDAQ:CATB)
www.schaeffersresearch.com - February 1 at 4:25 PM
rttnews.com logoCatabasis: Negative Mid-stage Clinical Trial Results For DMD Drug (NASDAQ:CATB)
www.rttnews.com - February 1 at 4:25 PM
investopedia.com logoCatabasis Tanks 70% on DMD Drug Failure (CATB) (NASDAQ:CATB)
www.investopedia.com - February 1 at 4:25 PM
smarteranalyst.com logoCowen’s Phil Nadeau Downgrades Catabasis Pharmaceuticals Inc (CATB), Slashes the Price Target to $4 (NASDAQ:CATB)
www.smarteranalyst.com - February 1 at 4:25 PM
marketwatch.com logoCatabasis Pharma stock sinks 69% after negative mid-stage clinical trial results for DMD drug (NASDAQ:CATB)
www.marketwatch.com - February 1 at 4:25 PM
insidermonkey.com logoCatabasis Pharmaceuticals Inc (CATB): What’s Next? (NASDAQ:CATB)
www.insidermonkey.com - February 1 at 4:25 PM
investopedia.com logoCatabasis Drops After Muscular Dystrophy Drug Fails (NASDAQ:CATB)
www.investopedia.com - February 1 at 4:25 PM
marketexclusive.com logoCatabasis Pharmaceuticals Inc (NASDAQ:CATB): What's Next? - Market Exclusive (NASDAQ:CATB)
marketexclusive.com - February 1 at 6:42 AM
streetinsider.com logoCatabasis Pharma (CATB) Reports Top-Line Results for Part B of MoveDMD Trial for Edasalonexent in DMD (NASDAQ:CATB)
www.streetinsider.com - January 31 at 9:34 PM
bizjournals.com logoCatabasis shares plummet on Duchenne trial failure (NASDAQ:CATB)
www.bizjournals.com - January 31 at 9:34 PM
finance.yahoo.com logoCatabasis Pharmaceuticals Announces Top-Line Results for Part B of the MoveDMD® Trial for Edasalonexent (CAT-1004) in Duchenne Muscular Dystrophy (NASDAQ:CATB)
finance.yahoo.com - January 31 at 4:34 PM
News IconCatabasis Pharmaceuticals Inc CATB Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:CATB)
www.bioportfolio.com - January 27 at 5:24 PM
News IconWhat Are the Numbers Saying About: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - The Tribune (NASDAQ:CATB)
lakecitytribune.com - January 26 at 10:01 PM
News IconTechnical Action Update on Shares of Catabasis Pharmaceuticals Inc (CATB) - Sherwood Daily (NASDAQ:CATB)
sherwooddaily.com - January 26 at 10:01 PM
News IconStock Seesawing as Volatility Sweeps in on Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Wall Street Beacon (NASDAQ:CATB)
wsbeacon.com - January 26 at 4:58 PM
News IconStock Cutting The Mustard Mid-Session: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Aiken Advocate (NASDAQ:CATB)
aikenadvocate.com - January 25 at 5:15 PM
News IconEnlivened Volatility Spotted in Shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Wall Street Beacon (NASDAQ:CATB)
wsbeacon.com - January 25 at 5:15 PM
News IconEquity Rundown: RSI and CCI Check on Catabasis Pharmaceuticals Inc (CATB) - Sherwood Daily (NASDAQ:CATB)
sherwooddaily.com - January 24 at 9:42 PM
News IconEarnings in Full Force, Analysts Take Aim at Catabasis Pharmaceuticals Inc (NASDAQ:CATB) - Wall Street Beacon (NASDAQ:CATB)
wsbeacon.com - January 24 at 9:42 PM
News IconShares Hitting The Skids, Bounding Lower Mid-Day: Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Wall Street Beacon (NASDAQ:CATB)
wsbeacon.com - January 23 at 9:26 PM
News IconPriming The Pump: Stock Volatility Spotted in Catabasis ... - Wall Street Beacon (NASDAQ:CATB)
wsbeacon.com - January 23 at 9:26 PM
investopedia.com logoCatabasis Reports Muscular Dystrophy Drug Data (CATB) (NASDAQ:CATB)
www.investopedia.com - January 23 at 4:26 PM
investopedia.com logoCatabasis Muscular Dystrophy Drug Posts Early Win (NASDAQ:CATB)
www.investopedia.com - January 23 at 4:26 PM
investing.com logoCatabasis Pharmaceuticals Shares Increase On Positive Phase 1 Results (NASDAQ:CATB)
www.investing.com - January 22 at 4:11 PM
News IconNext Weeks Broker Price Targets For Catabasis Pharmaceuticals, Inc. (CATB) (NASDAQ:CATB)
perspectivabetica.com - January 22 at 2:13 AM

Social

What is Catabasis Pharmaceuticals' stock symbol?

Catabasis Pharmaceuticals trades on the NASDAQ under the ticker symbol "CATB."

Where is Catabasis Pharmaceuticals' stock going? Where will Catabasis Pharmaceuticals' stock price be in 2017?

5 equities research analysts have issued 12-month price objectives for Catabasis Pharmaceuticals' stock. Their forecasts range from $4.00 to $16.00. On average, they expect Catabasis Pharmaceuticals' stock price to reach $9.80 in the next twelve months.

When will Catabasis Pharmaceuticals announce their earnings?

Catabasis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 28th 2017.

Who owns Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include SV Life Sciences Advisers LLC (15.32%), FMR LLC (7.38%), Deerfield Management Co. (3.66%), Alyeska Investment Group L.P. (1.20%), Federated Investors Inc. PA (0.86%) and Fred Alger Management Inc. (0.24%). Company insiders that own Catabasis Pharmaceuticals stock include Medimmune Ventures, Inc and Nicholas Galakatos.

Who sold Catabasis Pharmaceuticals stock? Who is selling Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., FMR LLC and Deerfield Management Co..

Who bought Catabasis Pharmaceuticals stock? Who is buying Catabasis Pharmaceuticals stock?

Catabasis Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA and Alyeska Investment Group L.P.. Company insiders that have bought Catabasis Pharmaceuticals stock in the last two years include Medimmune Ventures, Inc and Nicholas Galakatos.

How do I buy Catabasis Pharmaceuticals stock?

Shares of Catabasis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Catabasis Pharmaceuticals stock cost?

One share of Catabasis Pharmaceuticals stock can currently be purchased for approximately $1.22.

Catabasis Pharmaceuticals (NASDAQ:CATB) Chart for Monday, February, 27, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Earnings History Chart

Earnings by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Dividend History Chart

Dividend Payments by Quarter for Catabasis Pharmaceuticals (NASDAQ:CATB)

Last Updated on 2/27/2017 by MarketBeat.com Staff